Dr. Xiaokui Zhang (left), Dr. Albert Wong (center), and Dr. Preet Chaudhary (right) Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $750,000 to Dr. Xiaokui Zhang at Celularity to conduct a clinical trial for the treatment of COVID-19. This brings the total number of CIRM clinical trials to 64, including … Continue reading CIRM Board Approves Third Clinical Trial for COVID-19
Maria Millan
CIRM Board Approves Two Additional COVID-19 Projects
Dr. Vaithilingaraja Arumugaswami (left) and Dr. Song Li (right), UCLA Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved two additional projects as part of the $5 million in emergency funding for COVID-19 related projects. This brings the number of projects CIRM is supporting to 11, including two clinical trials. The Board awarded $349,999 … Continue reading CIRM Board Approves Two Additional COVID-19 Projects
A clear vision for the future
Dr. Henry Klassen and Dr. Jing Yang, founders of jCyte When you have worked with a group of people over many years the relationship becomes more than just a business venture, it becomes personal. That's certainly the case with jCyte, a company founded by Drs. Henry Klassen and Jing Yang, aimed at finding a cure … Continue reading A clear vision for the future
CIRM Board Funds its First Clinical Study for COVID-19
Dr. John Zaia, City of hope Today the governing Board of the California Institute for Regenerative Medicine (CIRM) continued its commitment to help with the coronavirus pandemic by awarding $749,999 to Dr. John Zaia at City of Hope. He will be conducting a clinical study to administer blood plasma from recovered COVID-19 patients to treat … Continue reading CIRM Board Funds its First Clinical Study for COVID-19
An advocate’s support for CIRM’s COVID-19 funding
Patient Advocates play an important role in everything we do at the stem cell agency, helping inform all the decisions we make. So it was gratifying to hear from one of our Advocates par excellence, Adrienne Shapiro, about her support for our Board's decision to borrow $4.2 million from our Sickle Cell Cure fund to … Continue reading An advocate’s support for CIRM’s COVID-19 funding
CIRM Board invests $5 million in emergency funding for coronavirus
Coronavirus In response to the crisis caused by the COVID-19 virus in California and around the world the governing Board of the California Institute for Regenerative Medicine (CIRM) today held an emergency meeting to approve $5 million in rapid research funds targeting the virus. “These are clearly extraordinary times and they require an extraordinary response … Continue reading CIRM Board invests $5 million in emergency funding for coronavirus
Big time validation for early support
It’s not every day that a company and a concept that you helped support from the very beginning gets snapped up for $4.9 billion. But that’s what is happening with Forty Seven Inc. and their anti-cancer therapies. Gilead, another California company by the way, has announced it is buying Forty Seven Inc. for almost $5 … Continue reading Big time validation for early support
CIRM Board Meeting Highlights Important Updates to Clinical Trials
Dr. Maria T. Millan, President and CEO of CIRM, presenting the President's Report This past Thursday the governing Board of the California Institute for Regenerative Medicine (CIRM) were presented with an update on CIRM’s clinical portfolio, which to date includes 60 clinical trials in various areas including kidney failure, cancer, and other rare diseases. The … Continue reading CIRM Board Meeting Highlights Important Updates to Clinical Trials
CIRM’s Alpha Stem Cell Clinics Given High Profile Role in Clinical Trials Network
Sue and Bill Gross Hall Photo by Hoang Xuan Pham/ UC Irvine There are a growing number of predatory clinics in California and around the US, offering unproven stem cell therapies. For patients seeking a legitimate therapy it can often be hard finding a reliable clinic, one offering treatments based on the rigorous science required … Continue reading CIRM’s Alpha Stem Cell Clinics Given High Profile Role in Clinical Trials Network
Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness
The governing Board of the California Institute for Regenerative Medicine (CIRM) yesterday invested $32.92 million to fund the Stem Cell Agency’s first clinical trial in Parkinson’s disease (PD), and to support three clinical trials targeting different forms of vision loss. This brings the total number of clinical trials funded by CIRM to 60. The PD … Continue reading Stem Cell Agency Approves Funding for Clinical Trials Targeting Parkinson’s Disease and Blindness
The Stem Cellar 